



# Exploration the potential mechanism of the SIRT1 and its target gene *FOXO1/PPARGC1A* in uteropelvic junction obstruction

Qian Zhao, Ge Liu, Xiaoming Yin, Xu Fan, Yi Yang

Department of Pediatric Urology, Shengjing Hospital of China Medical University, Shenyang, China

**Contributions:** (I) Conception and design: Q Zhao, Y Yang; (II) Administrative support: Y Yang; (III) Provision of study materials or patients: Q Zhao, Y Yang; (IV) Collection and assembly of data: G Liu, X Yin; (V) Data analysis and interpretation: X Fan; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Yi Yang. Department of Pediatric Urology, Shengjing Hospital of China Medical University, 36 Sanhao Street, Shenyang 110004, China. Email: yangyilab@163.com.

**Background:** Uteropelvic junction obstruction (UPJO) is a common surgical condition, which refers to the blockage of urine flowing through kidney into proximal upper ureter. However, the underlying mechanism of UPJO is poorly understood, especially the regulated and targeted genes of sirtuin 1 in UPJO.

**Methods:** We sequenced three renal tissues on the obstructed side of independent children with <20% differential renal function (DRF) and three samples with >40% DRF. Gene expression values were obtained and compared for differentially expressed genes (DEGs). Protein-protein interaction (PPI) analysis was conducted to identify the overlapping proteins of DEGs and Sirtuin 1 (SIRT1). The co-expression genes of overlapped genes were computed using Pearson correlation coefficient. The potential role of *SIRT1* gene in UPJO was explored by resequencing 3 microarray data from RNA interference (RNAi) SIRT1 lines of renal tubular epithelial (NRK52E) cells in rat and three control datasets were sequenced again. The DEGs were obtained as parallel. GO/KEGG enrichment analysis and co-expression network were conducted to explore the underlying mechanism, particularly shared pathways or function in GO/KEGG enrichment analysis results.

**Results:** A total of 427 up-regulated genes and 1,099 down-regulated genes were identified among 3 mRNA-seq of renal tissue on the obstructed side of the independent children with <20% DRF and 3 samples with >40% DRF. According to prediction using the Search Tool for Retrieval of Interacting Genes/Proteins, 2 PPIs, FOXO1 and PPARGC1A, were identified among 2,524 DEGs, predicted as targets of *SIRT1*. Gene set enrichment analysis (GSEA) of their co-expression genes showed they may co-participate in biological activities including fatty acid degradation, regulation of signal transduction by p53 mediator. Moreover, GSEA results of DEGs was confirmed through RNAi SIRT1 lines of rat renal tubular epithelial (NRK52E) cells.

**Conclusions:** UPJO may cause abnormal phenotypic changes of renal tubular epithelial cells through SIRT1/FOXO1 mediated protein transport, establishment of protein localization, and intracellular transport. In addition, UPJO is involved in regulation of signal transduction, regulation of intracellular estrogen receptor signaling pathways, and nucleoprotein localization through SIRT1/PPARGC1A-mediated p53 mediators, causing abnormal phenotypic changes in renal tubular epithelial cells.

**Keywords:** Uteropelvic junction obstruction (UPJO); Sirtuin 1 (SIRT1); FOXO1; PPARGC1A; kidney function

Submitted Aug 06, 2021. Accepted for publication Oct 09, 2021.

doi: 10.21037/tau-21-752

View this article at: <https://dx.doi.org/10.21037/tau-21-752>

## Introduction

Ureteropelvic junction obstruction (UPJO) is a common congenital surgical condition (1-3). It involves blockage of the flow of urine through the kidney into proximal upper ureter. The pathogenesis of UPJO can be explained by gross changes in the ureteral wall (4,5). The majority of UPJO cases are congenital and caused by mechanical ureteral obstruction (4,6). Timely treatment of UPJO is important to avoid chronic infection, urolithiasis, and frequent deterioration of renal function (7,8). Although UPJO be addressed surgically, some patients still experience kidney disease after surgery. The damage does not recover or even progresses, and the long-term renal function deteriorates, eventually requiring hemodialysis and kidney transplantation, which seriously affects the quality of life of children and their families (9-11). Although it is a fairly common disease, there is still a lack of understanding of the underlying mechanism of UPJO. Recently, several studies have reported that many different proteins participate in regulating the formation of mechanical ureteral obstruction and leading to UPJO (12). However, in-depth research on the regulation mechanism of early renal injury in obstructive nephropathy, early diagnosis and early treatment, and delaying the renal function damage caused by obstructive nephropathy, has great economic and social significance in the familial and broader social settings.

Silent information regulator factor 2-related enzyme 1 (Sirtuin 1, SIRT1) is an important protein of the class III histone deacetylases family, which performed as a nicotinamide adenine dinucleotide-dependent deacetylase, participating in deacetylating histone proteins and other transcription factors. SIRT could also regulate many different biological processes such as gene transcription, energy metabolism, and oxidative stress (13-24). Abundantly expressed in the kidney, SIRT1 participated in renal physiologic and pathologic phenotypes. In addition to the unilateral ureteral obstruction model, the up-regulation of SIRT1 in murine renal medullary interstitial cells was reported to repress the COX2 level during oxidative stress-induced to recovery the interstitium from inflammation and fibrogenesis (25). Moreover, the SIRT1 knockout mice was showed to be impairment of angiogenesis, reduction of matrilytic activity, and retention of the profibrotic cleavage substrate tissue transglutaminase as well as endoglin-accompanied MMP-14 suppression (26-28). Recovery of MMP-14 expression in SIRT1-knock out mice was reported as many phenotypic changes including

improving the angiogenic and matrilytic functions of the endothelium, inhibiting renal dysfunction, even attenuating nephrosclerosis (29). SIRT1 is a promising drug targeting for inhibiting the progression of nephrosclerosis. There have been some experiments of acute nutrient withdrawal which have mentioned that the forkhead transcription factor Foxo3a could be stimulated during interacting with p53 (25,30). Through combining 2 p53 binding sites at SIRT1 promoter, Foxo3a could induce the transcription of SIRT1.

However, the role and potential mechanism of the SIRT1 and its target gene *FOXO1/PPARGC1A* in UPJO remain unclear. We firstly investigated the regulatory role of SIRT1 and its downregulated gene expression during UPJO through RNA sequence. Therefore, we explored the expression change of genes regulated by SIRT1 in RNAi SIRT1 lines of rat renal tubular epithelial (NRK52E) cells, in which the expression of *SIRT1* was knocked down. Concurrently, we compared the differential expression between messenger RNA (mRNA)-seq data of the renal tissue on the obstructed side of children with <20% DRF and 3 samples with >40% DRF. To further explore SIRT1, we analyzed its effect based on the prediction of protein-protein interaction (PPI). We studied the related signaling pathway through Gene Ontology/Kyoto Encyclopedia of Genes and Genomes (GO/KEGG) enrichment analysis and conducted SIRT1-related co-expression network. In summary, the aim of our study was to examine the potential mechanism of the SIRT1 and its target gene *FOXO1/PPARGC1A* in UPJO. We present the following article in accordance with the MDAR reporting checklist (available at <https://dx.doi.org/10.21037/tau-21-752>).

## Methods

### *Clinical data acquisition and extraction*

The mRNA-seq samples were from renal tissue on the obstructed side of the independent children with unilateral UPJO undergoing surgical treatment from Department of Pediatric Urology, Shengjing Hospital of China Medical University, the differential renal function in the treatment group was less than 20%, indicating severely impairment, while it was greater than 40% in the control group, indicating that the renal function was not impaired or was slightly injured. The admission criteria for children in the treatment group was the renal dynamic scan, which indicated that their renal function was less than 20%. The entry criteria for children in the control group was that

the radionuclide examination indicated that their kidney function was greater than 40%. The age of children at the time of surgery ranged from 6 to 18 weeks, or 1.5 to 5 months, and all participants were boys. Specimens of kidney tissue were acquired from the children during surgery. After the samples were collected, they were placed directly in liquid nitrogen, and then transferred to storage at  $-80^{\circ}\text{C}$  until the time of inspection. All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by institutional Ethics Review Board of Shengjing Hospital of China Medical University (No. 2013PS81K) and informed consent was taken from all the patients.

### ***Cell culture, transfection and RT-qPCR***

Normal rat kidney 52E (NRK52E) cells were purchased from American Type Culture Collection (ATCC), cultured in Dulbecco's modified Eagle medium (DMEM; Gibco, Life Technologies, Carlsbad, CA, USA) containing 10% heat-inactivated fetal bovine serum (FBS; Corning, Corning, NY, USA) and 1% antibiotic-antimycotic (Gibco, Life Technologies, USA).

The small interfering RNA (siRNA) of SIRT1 was transfected in the NRK52E cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. RT-qPCR was used to detect the expression SIRT1 after transfection for 24 h.

### ***Differentially expressed genes***

The samples were grouped based on the information of the samples, and the differential expression values of sequencing data were calculated by R package edgeR (<https://cran.r-project.org/web/packages/edgeRun/edgeRun.pdf>) (31) and balltown software. Based on the cutoff of false discovery rate (FDR) value 0.05, differentially expressed genes (DEGs) from the mRNA-seq were determined with the following threshold value:  $\log_2$  |fold change (FC)|  $\geq 1.2$ , and DEGs from the microarray data were determined with the threshold value  $\log_2$  |fold change|  $\geq 1.5$ .

### ***PPI network prediction***

The online tool of Search Tool for Retrieval of Interacting Genes/Proteins (STRING) (32) was used to predict the PPI of the *SIRT1* gene. At the same time, the required

confidence (combined score)  $>0.7$  was selected as the threshold value of PPI.

### ***Construction of co-expression network***

A co-expression network was constructed with gene pairs with Pearson correlation coefficient (PCC) values calculated by R of greater than 0.99. The co-expression network is displayed by Cytoscape (<https://cytoscape.org/>) (33).

### ***GO/KEGG enrichment analysis***

Based on the GO (34) and KEGG pathway databases (35), the candidate genes were used to conduct GO/KEGG functional enrichment. The statistical algorithm (Fisher's exact test) was used to determine which specific functional items were most related to a group of genes. Each item in the analysis results corresponds to a statistical P value to represent significance. The smaller the P value, the greater the relationship between the item and the input genes, that is, most of the genes in the group had the function described by the term. The whole analysis procedure was showed in *Figure 1*.


### ***Statistical analysis***

GraphPad Prism 8 were performed for analysis. R package edgeR (<https://cran.r-project.org/web/packages/edgeRun/edgeRun.pdf>) was used to calculate the differential expression values. Retrieval of Interacting Genes/Proteins (STRING) was used for PPI network prediction. Cytoscape (<https://cytoscape.org/>) was performed for construction of co-expression network. The mRNA expression quantification was performed using  $2^{-\Delta\Delta\text{Ct}}$  values. Statistical significance was defined as  $P < 0.05$ .

## **Results**

### ***Identification of DEGs***

A total of six mRNA-seq samples were available for further analysis, including three samples from the renal tissue on the obstructed side of the independent children with less than 20% DRF and three samples from renal tissue on the obstructed side of the independent children with greater than 40% DRF. The gene expression values in these samples were obtained and compared for DEGs between samples of renal tissue on the obstructed side of the experimental



**Figure 1** Flow diagram of the analysis procedure: data sources, preprocessing, analysis and validation. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; UPJO, ureteropelvic junction obstruction.

group and the three control group samples. Accordingly, 1,427 up-regulated genes and 1,099 down-regulated genes were acquired in the mRNA-seq data sets from the renal tissue on the obstructed side of the experimental group samples versus the control group samples (Figure 2A). The up-regulated genes included *ADIPOQ*, *GSTT1*, and *GSTM1*, among others, while the down-regulated genes were *KCNE1B*, *RGPD2*, and *HLA-DRB5*, among others. In addition, 3 microarray data from RNAi SIRT1 lines of rat renal tubular epithelial (NRK52E) cells and 3 control microarray data were sequenced to explore the potential role of genes regulated or targeted by *SIRT1* in UPJO. Similarly, the expression levels of genes in these samples were obtained for computing the DEGs. As a result, there were 2,382 up-regulated genes and 2,138 down-regulated genes in RNAi SIRT1 lines of rat renal tubular epithelial (NRK52E) cells, respectively (Figure 2B). The up-regulated genes included *Wrb*, *Col1a1*, *Fam198b*, and others, while the down-regulated genes were *Loxl2*, *Plscr1*, *Nucks1*, and so on.


#### Prediction of the target genes of SIRT1 in UPJO

Firstly, the proteins that interact with SIRT1 were predicted


using the online tools in STRING. From the perspective of PPI network of SIRT1 (Figure 3A), the interacting relationships covering 11 proteins were shown clearly. For example, SIRT1 protein was shown to interact with FOXO1, PPARGC1A, EP300, and so on. Among these interacted proteins, SIRT1 and HDAC1 are members of the histone deacetylases family (36). To further ensure the key target genes of SIRT1, overlap analysis was conducted on DEGs from RNA-seq and the SIRT1-interacted proteins (Figure 3B). We took all 2,526 up/down-regulated genes (DEGs) from mRNA-seq samples of the renal tissue on the obstructed side of the experimental group versus the control group samples to analyze the overlap with SIRT1-interacted proteins. Then, there were only 2 overlap genes remaining of potential importance in the pathways related with SIRT1. The 2 genes were *FOXO1* ( $\log_2\text{FD} = -0.30$ ,  $P = 0.035$ ) and *PPARGC1A* ( $\log_2\text{FD} = -0.62$ ,  $P = 0.0002$ ), which may be the target genes of SIRT1 in UPJO.

#### The prediction of pathway related to SIRT1 through the co-expression network

Firstly, *FOXO1* gene was selected for construction of its



**Figure 2** Volcano maps of differential expressed genes. (A) A volcano map of differential expressed genes from mRNA-seq samples of renal tissue on the obstructed side of children with less than 20% DRF versus the 3 samples with greater than 40% DRF; (B) a volcano map of differential expressed genes from RNAi SIRT1 lines of rat renal tubular epithelial (NRK52E) cells versus control samples. The x axis in the map is the fold change of relative expression rates between the 2 samples (with logarithmic treatment), and the y axis is the statistical test value, i.e., P value. The higher  $-\log_{10}$  (P value) was, the more significant the difference was. Each dot in the graph demonstrated a gene, the red dot shows the up-regulative gene, the blue dot indicates the down-regulative gene, and the gray dot indicates no significant difference gene. DRF, differential renal function; mRNA, messenger RNA.



**Figure 3** PPI network of SIRT1 and its Venn diagram. (A) Nodes represent genes and edges indicate interaction between 2 proteins. The more edges connected to a node, the more important the protein is in the network. (B) Venn diagram of 2 gene sets. One gene set in red represents the DEGs obtained from the mRNA-seq data of the renal tissue on the obstructed side of the independent children with <20% DRF versus samples with >40% DRF. The other gene set in blue indicates the proteins interacted with *SIRT1* gene. PPI, protein-protein interaction; DEG, differentially expressed gene; DRF, differential renal function.

co-expression networks, respectively. Firstly, co-expression FOXO1 and its GSEA were mainly identified based on their intersecting PCC values, the results showed the co-expression genes of *FOXO1* were shown to include *ZC3H15*, *ZZZ3*, *ANO10*, *INVS*, and *UBE2G1* (Figure 4A). We conducted enrichment analysis of the down-regulated genes from mRNA-seq samples of the renal tissue on the obstructed side of the experimental group due to the down-regulation gene FOXO1. Positive expression with *FOXO1* was detected in these genes. Through GO enrichment analysis of *FOXO1*, the co-expression genes were shown to be mainly enriched in the process of carboxylic acid metabolism, organic acid metabolism, monocarboxylic acid metabolism, carboxylic acid decomposition, and other biological processes (BP; Figures 4B). In KEGG pathways, they mainly involved in metabolic pathways, fatty acid degradation, and the degradation of valine, leucine, and isoleucine (Figure 4C). Moreover, the heatmap of GO enrichment analysis results (Figure 5A) and the heatmap of GO enrichment analysis results with the fold change of gene expression (Figure 5B) were also proved that the co-expression genes were enriched in those biological processes.

Then, co-expression *PPARGC1A* and their GSEA were mainly demonstrated dependent on their intersecting PCC values (Figure 6A), and the co-expression genes of *PPARGC1A* included *GOLIM4*, *CHORDC1*, *ZNF470*, *SLTM*, *KIF16B*, and so forth. The co-expression genes of *PPARGC1A* were subjected to GO (Figure 6B) enrichment analysis. The co-expression genes of *PPARGC1A* were mainly enriched in the GO terms of protein localization to nucleolus, regulation of signal transduction by class p53 mediator, monocarboxylic acid metabolism, carboxylic acid decomposition, and other BP (Figures 6B, 7A, 7B), while there were no significant enriched terms in the analysis of KEGG pathway for them.

#### ***Further validation of pathways related to SIRT1 in RNAi SIRT1 lines of rat renal tubular epithelial (NRK52E) cells***


To further validate the pathways related to SIRT1, we conducted the GO enrichment analysis of up-regulated genes in RNAi SIRT1 lines of rat renal tubular epithelial (NRK52E) cells versus control samples. After RNAi SIRT1 lines of rat renal tubular epithelial (NRK52E) cells, RT-qPCR was performed to confirm that the expression of SIRT1 in SIRT1-RNAi NRK52E cells was significantly downregulated (Figure S1). However, there is not significant phenotype change of NRK52E cells before and after RNAi

Sirt transfection (photos were not showed). The analysis results suggested that these genes are mainly enriched in BP such as positive regulation of protein metabolism, tissue development, regulation of protein metabolism process, and regulation of signal transduction (Figure 8A). The KEGG pathway enrichment analysis revealed that they were likely involved in cancer associated proteoglycan, AGE-RAGE signaling pathway, FOXO signaling pathway, endocrine resistance, and other signaling pathways (Figure 8B).

Next, we performed Venn diagram analysis of the above GO terms and *FOXO1/PPARGC1A* co-expression gene enrichment results (Figure 8C, 8D). On the one hand, it was revealed that *FOXO1* co-expressed gene enrichment results and RNAi sirt1 cell lines' enrichment results shared 85 GO BP terms (Table 1), mainly including protein transport, establishment of protein localization, intracellular transport, regulation of ubiquitin-dependent protein catabolism, and other biological processes. Accordingly, UPJO may cause abnormal phenotypic changes of renal tubular epithelial cells through SIRT1/FOXO1 mediated protein transport, the establishment of protein localization, and intracellular transport. On the other hand, it was shown that *PPARGC1A* co-expression gene enrichment results and RNAi SIRT1 cell lines' enrichment results shared 21 GO BP terms (Table 2), including p53-type mediators to regulate signal transduction, the regulation of intracellular estrogen receptor signaling pathways, nuclear protein localization and other BP. Overall, it was determined that UPJO regulates signal transduction, regulation of intracellular estrogen receptor signaling pathways, and nucleoprotein localization through SIRT1/PPARGC1A-mediated p53 mediators, causing abnormal phenotypic changes in renal tubular epithelial cells.

## **Discussion**

The disease UPJO is characterized by the blockage during urine flowing through the kidney into proximal upper ureter. The pathogenesis of UPJO is related to gross changes in the ureteral wall (4,5). Therefore, we analyzed samples from the renal tissues of children with DRF <20% and >40%. There were 427 up-regulated genes and 1,099 down-regulated genes obtained from the datasets from the renal tissues of children with DRF <20% versus with samples with DRF >40%. Differential analysis was also performed in the RNAi SIRT1 cell lines and control cell lines, which indicated the expression changes of genes might be regulated or targeted by SIRT1 in the UPJO-related




**Figure 4** The co-expression network of gene *FOXO1* and their GSEA. (A) The co-expression network of gene *FOXO1*. (B) GO enrichment analysis of the co-expression genes of *FOXO1*. The x axis demonstrated the GO term, and the y axis show the enrichment level, corresponding to the height of the column. The greater the enrichment score value, the more significant the GO term is enriched. The 3 colors represent 3 categories: biological process (BP), cellular component (CC) and molecular function (MF). (C) KEGG pathway enrichment analysis of the co-expression genes of *FOXO1*. The vertical axis showed the KEGG pathway name, and the horizontal axis represents enrichment score. The larger the value, the greater the enrichment degree. The size represents the genes' number in the pathway, and the color of the point represents the different P value. GSEA, gene set enrichment analysis; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.



**Figure 5** The heatmap of GO enrichment analysis results from *FOXO1* and co-expressed genes. (A) The heatmap of GO enrichment analysis results; (B) The heatmap of GO enrichment analysis results with the fold change of gene expression rates between the two samples (with logarithmic treatment). The x axis represents the DEGs, and the y axis represents the GO term. The color in purple indicates the fold change of gene expression rates between the two samples (with logarithmic treatment). GO, Gene Ontology; DEG, differentially expressed gene.








**Figure 7** The heatmap of GO enrichment analysis results from *PPARGC1A* and co-expressed genes. (A) The heatmap of GO enrichment analysis results. (B) The heatmap of GO enrichment analysis results with the fold change of gene expression rates between the two samples (with logarithmic treatment). The x axis represents the DEGs, and the y axis represents the GO term. The color in purple indicates the fold change of gene expression rates between the 2 samples (with logarithmic treatment). GO, Gene Ontology; DEG, differentially expressed gene.





**Figure 8** Analysis of up-regulated genes in RNAi SIRT1 lines versus control lines. (A) GO enrichment analysis of the up-regulated genes in RNAi SIRT1 lines. The x axis represents the GO term, and the y axis represents the significance level of enrichment, corresponding to the height of the column. The greater the enrichment score value, the more significant the GO term is enriched. (B) KEGG pathway enrichment analysis of the up-regulated genes in RNAi sirt1 lines. The vertical axis represents the KEGG pathway name, and the horizontal axis represents enrichment score. The larger the value, the greater the enrichment degree. The size of the point indicates the number of genes in the pathway, and the color of the point corresponds to different P value ranges. (C) Venn diagram of 2 GO term gene sets. One gene set in blue represents the all GO terms (BP, CC, MF) obtained from the enrichment analysis of the up-regulated genes in RNAi sirt1 lines. The other gene set in red indicates all GO terms (BP, CC, MF) from enrichment analysis of the co-expression genes of *FOXO1*. (D) Venn diagram of two GO term gene sets. One gene set in blue represents the all GO terms (BP, CC, MF) obtained from the enrichment analysis of the up-regulated genes in RNAi sirt1 lines. The other gene set in red indicates all GO terms (BP, CC, MF) from enrichment analysis of the co-expression genes of *PPARGC1A*. The circles with different colors show the GO terms of different sample groups, the values represent the common or unique GO terms among different groups, the sum of all numbers in the circle showed the total number of GO terms in the group, and the cross area of the circle represents the total number of GO terms among the groups. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; BP, biological process; CC, cellular component; MF, molecular function.

**Table 1** Partial shared BP terms from the enrichment analysis of the up-regulated genes in RNAi SIRT1 cell lines and the co-expression genes of *PPARGC1A*

ID	Term
GO:0015031	protein_transport
GO:0015833	peptide_transport
GO:0045184	establishment_of_protein_localization
GO:0046907	intracellular_transport
GO:2000058	regulation_of_ubiquitin-dependent_protein_catabolic_process

BP, biological process; GO, Gene Ontology.

**Table 2** Partial shared BP term from the enrichment analysis of the up-regulated genes in RNAi sirt1 cell lines and the co-expression genes of *FOXO1*

ID	Term
GO:1901796	regulation_of_signal_transduction_by_p53_class_mediator
GO:0033146	regulation_of_intracellular_estrogen_receptor_signaling_pathway
GO:0034504	protein_localization_to_nucleus
GO:0033143	regulation_of_intracellular_steroid_hormone_receptor_signaling_pathway
GO:0030162	regulation_of_proteolysis

BP, biological process; GO, Gene Ontology.

is involved in SIRT1/PPARGC1A-mediated p53 regulation of signal transduction and intracellular estrogen receptor signaling pathways on the account of nucleoprotein localization, and leads to abnormal phenotypic changes in renal tubular epithelial cells. However, there is some limitation that we did not identify the directly regulation effect among SIRT1, FOXO1 and PPARGC1A.

### Conclusions

We concluded that UPJO may cause abnormal phenotypic changes of renal tubular epithelial cells through SIRT1/FOXO1 mediated protein transport, the establishment of protein localization, and intracellular transport. In

the meantime, UPJO is involved in regulation of signal transduction, regulation of intracellular estrogen receptor signaling pathways, and nucleoprotein localization through SIRT1/PPARGC1A-mediated p53 mediators, causing abnormal phenotypic changes in renal tubular epithelial cells.

### Acknowledgments

*Funding:* National Natural Science Foundation of China (grant No. 81571514), 345 talent project and Key Research and Develop Program Collaborative Planning Project of Liaoning Province (2020JH 2/10300145)

### Footnote

*Reporting Checklist:* The authors have completed the MDAR reporting checklist (available at <https://dx.doi.org/10.21037/tau-21-752>).

*Data Sharing Statement:* Available at <https://dx.doi.org/10.21037/tau-21-752>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <https://dx.doi.org/10.21037/tau-21-752>). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by institutional Ethics Review Board of Shengjing Hospital of China Medical University (No.: 2013PS81K) and informed consent was taken from all the patients.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

### References

1. Cui X, He YB, Huang WH, et al. Mini-laparoscopic pyeloplasty to treat UPJO in infants. *Minim Invasive Ther Allied Technol* 2020. [Epub ahead of print].
2. Zhang P, Shi T, Fam X, et al. Robotic-assisted laparoscopic pyeloplasty as management for recurrent ureteropelvic junction obstruction: a comparison study with primary pyelo-plasty. *Transl Androl Urol* 2020;9:1278-85.
3. Tabari AK, Atqiaee K, Mohajerzadeh L, et al. Early pyeloplasty versus conservative management of severe ureteropelvic junction obstruction in asymptomatic infants. *J Pediatr Surg* 2020;55:1936-40.
4. Krajewski W, Wojciechowska J, Dembowski J, et al. Hydronephrosis in the course of ureteropelvic junction obstruction: An underestimated problem? Current opinions on the pathogenesis, diagnosis and treatment. *Adv Clin Exp Med* 2017;26:857-64.
5. Longpre M, Nguan A, Macneily AE, et al. Prediction of the outcome of antenatally diagnosed hydronephrosis: a multivariable analysis. *J Pediatr Urol* 2012;8:135-9.
6. Vandervoort K, Lasky S, Sethna C, et al. Hydronephrosis in infants and children: natural history and risk factors for persistence in children followed by a medical service. *Clin Med Pediatr* 2009;3:63-70.
7. Carlström M. Hydronephrosis and risk of later development of hypertension. *Acta Paediatr* 2019;108:50-7.
8. Kandur Y, Salan A, Guler AG, et al. Diuretic renography in hydronephrosis: a retrospective single-center study. *Int Urol Nephrol* 2018;50:1199-204.
9. Chaabane W, Praddaude F, Buleon M, et al. Renal functional decline and glomerulotubular injury are arrested but not restored by release of unilateral ureteral obstruction (UUO). *Am J Physiol Renal Physiol* 2013;304:F432-9.
10. Chevalier RL, Forbes MS, Galarreta CI, et al. Responses of proximal tubular cells to injury in congenital renal disease: fight or flight. *Pediatr Nephrol* 2014;29:537-41.
11. Liu BC, Tang TT, Lv LL, et al. Renal tubule injury: a driving force toward chronic kidney disease. *Kidney Int* 2018;93:568-79.
12. Wu B, Gong X, Kennedy WA, et al. Identification of transcripts associated with renal damage due to ureteral obstruction as candidate urinary biomarkers. *Am J Physiol Renal Physiol* 2018;315:F16-26.
13. Alves-Fernandes DK, Jasiulionis MG. The Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in

- Cancer. *Int J Mol Sci* 2019;20:3153.
14. Farghali H, Kemelo MK, Canová NK. SIRT1 Modulators in Experimentally Induced Liver Injury. *Oxid Med Cell Longev* 2019;2019:8765954.
  15. Lu G, Li J, Zhang H, et al. Role and Possible Mechanisms of Sirt1 in Depression. *Oxid Med Cell Longev* 2018;2018:8596903.
  16. Meng X, Tan J, Li M, et al. Sirt1: Role Under the Condition of Ischemia/Hypoxia. *Cell Mol Neurobiol* 2017;37:17-28.
  17. Han Y, Sun W, Ren D, et al. SIRT1 agonism modulates cardiac NLRP3 inflammasome through pyruvate dehydrogenase during ischemia and reperfusion. *Redox Biol* 2020;34:101538.
  18. Iside C, Scafuro M, Nebbioso A, et al. SIRT1 Activation by Natural Phytochemicals: An Overview. *Front Pharmacol* 2020;11:1225.
  19. Li T, Garcia-Gomez A, Morante-Palacios O, et al. SIRT1/2 orchestrate acquisition of DNA methylation and loss of histone H3 activating marks to prevent premature activation of inflammatory genes in macrophages. *Nucleic Acids Res* 2020;48:665-81.
  20. Nagappan A, Kim JH, Jung DY, et al. Cryptotanshinone from the *Salvia miltiorrhiza* Bunge Attenuates Ethanol-Induced Liver Injury by Activation of AMPK/SIRT1 and Nrf2 Signaling Pathways. *Int J Mol Sci* 2019;21:265.
  21. Rada P, Pardo V, Mobasher MA, et al. SIRT1 Controls Acetaminophen Hepatotoxicity by Modulating Inflammation and Oxidative Stress. *Antioxid Redox Signal* 2018;28:1187-208.
  22. Strycharz J, Rygielska Z, Swiderska E, et al. SIRT1 as a Therapeutic Target in Diabetic Complications. *Curr Med Chem* 2018;25:1002-35.
  23. Zhang Y, Anoopkumar-Dukie S, Arora D, et al. Review of the anti-inflammatory effect of SIRT1 and SIRT2 modulators on neurodegenerative diseases. *Eur J Pharmacol* 2020;867:172847.
  24. Zhao S, Li W, Cheng F, et al. High-pressure carbon dioxide pneumoperitoneum induces oxidative stress and mitochondria-associated apoptotic pathway in rabbit kidneys with severe hydronephrosis. *Int J Mol Med* 2019;43:305-15.
  25. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. *Science* 2004;306:2105-8.
  26. Jiang Y, Botchway BOA, Hu Z, et al. Overexpression of SIRT1 Inhibits Corticosterone-Induced Autophagy. *Neuroscience* 2019;411:11-22.
  27. Mokhberian N, Hashemi SM, Jajarmi V, et al. Sirt1 antisense transcript is down-regulated in human tumors. *Mol Biol Rep* 2019;46:2299-305.
  28. Zhang D, Sun X, Chen X, et al. Ultrasound evaluation for prediction of outcomes and surgical decision in fetal hydronephrosis. *Exp Ther Med* 2019;18:1399-406.
  29. Vasko R, Xavier S, Chen J, et al. Endothelial sirtuin 1 deficiency perpetrates nephrosclerosis through downregulation of matrix metalloproteinase-14: relevance to fibrosis of vascular senescence. *J Am Soc Nephrol* 2014;25:276-91.
  30. Ma F, Wu J, Jiang Z, et al. P53/NRF2 mediates SIRT1's protective effect on diabetic nephropathy. *Biochim Biophys Acta Mol Cell Res* 2019;1866:1272-81.
  31. McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation. *Nucleic Acids Res* 2012;40:4288-97.
  32. von Mering C, Huynen M, Jaeggi D, et al. STRING: a database of predicted functional associations between proteins. *Nucleic Acids Res* 2003;31:258-61.
  33. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res* 2003;13:2498-504.
  34. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. *Nat Genet* 2000;25:25-9.
  35. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* 2000;28:27-30.
  36. Pfister JA, Ma C, D'Mello SR. Catalytic-independent neuroprotection by SIRT1 is mediated through interaction with HDAC1. *PLoS One* 2019;14:e0215208.
  37. Imai S, Guarente L. Ten years of NAD-dependent SIR2 family deacetylases: implications for metabolic diseases. *Trends Pharmacol Sci* 2010;31:212-20.
  38. Cheng Z, Guo S, Copps K, et al. Foxo1 integrates insulin signaling with mitochondrial function in the liver. *Nat Med* 2009;15:1307-11.
  39. Charos AE, Reed BD, Raha D, et al. A highly integrated and complex PPARGC1A transcription factor binding network in HepG2 cells. *Genome Res* 2012;22:1668-79.
- (English Language Editor: J. Jones)

**Cite this article as:** Zhao Q, Liu G, Yin X, Fan X, Yang Y. Exploration the potential mechanism of the SIRT1 and its target gene *FOXO1/PPARGC1A* in uteropelvic junction obstruction. *Transl Androl Urol* 2021;10(11):4192-4205. doi: 10.21037/tau-21-752




Figure S1 The RT-qPCR results of Sirt1 expression level (\*\*P<0.01).